Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024 DOI Creative Commons
Xiaoling Zhong,

Yihan Yang,

Sheng Wei

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 22, 2024

Abstract Background Finasteride is commonly utilized in clinical practice for treating androgenetic alopecia, but real-world data regarding the long-term safety of its adverse events remains incomplete, necessitating ongoing supplementation. This study aims to evaluate (AEs) associated with finasteride use, based on from US Food and Drug Administration Adverse Event Reporting System (FAERS), contribute assessment. Methods We reviewed event reports FAERS database, covering period first quarter 2004 2024. assessed medication AEs using four proportional disproportionality analyses: reported odds ratio, proportionate reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPN), Multi-Item Gamma Poisson Shrinkage (MGPS). These methods were used AEs. whether there a significant association between drug use To investigate potential issues related we further analyzed similarities differences onset time by gender, as well age. Results Among 11,557 where was primary suspected drug, most patients affected male (86.04%), proportion being young adult aged 18-45 years (27.22%). categorized 73 into 7 different system organ categories (SOCs), which included common like erectile dysfunction sexual dysfunction. Notably, Peyronie’s disease post 5α reductase inhibitor syndrome not listed insert. identified 102 men women. Depression anxiety notable both female. Additionally, examined 17 under 18 old, 157 65 years, 133 older. Each age group exhibited unique AEs, although dysfunction, decreased libido, depression, suicidal ideation, psychotic disorder, attention disturbance observed across brackets. Ultimately, median all instances 61 days. The mainly within one month after initiation it noteworthy that second highest number cases involved reactions persisted beyond year treatment. Conclusion results our uncovered known novel medication. Some these identical specification, some them signaled demonstrated specification. In addition, showed variations gender study. Consequently, findings offer valuable insights future research are anticipated enhance safe practice.

Language: Английский

Synergizing Success: The Role of Anlotinib Combinations in Advanced Non-Small Cell Lung Cancer Treatment DOI Creative Commons
‏Helal F. Hetta, Hashim M. Aljohani,

Nizar Sirag

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 585 - 585

Published: April 16, 2025

Anlotinib, a novel receptor tyrosine kinase inhibitor that is taken orally, targets several RTKs and authorized as third-line treatment for patients with advanced non-small cell lung cancer (NSCLC). Anlotinib also used in combination immunotherapy or chemotherapy NSCLC. We aimed to explore the efficacy safety of anlotinib-based regimens NSCLC treatment, focusing on therapies. addressed challenges hinder oncologists from using it, such toxicity resistance mechanisms. A systematic approach involves searching National Institute Health PubMed, Scopus, MedLine, Web Science databases up April 2024. Relevant studies were identified analyzed their methodologies, outcomes, patient characteristics. Findings revealed numerous effective regimens, anlotinib platinum-based combined PD-1 blockades, have shown positive results terms progression-free survival (PFS), overall (OS), objective response rate (ORR). On other hand, faces hurdles due drug its profile. These underscore need continued research optimization strategies.

Language: Английский

Citations

1
Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023 DOI Creative Commons
Yihan Yang, Sheng Wei, Huan Tian

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: July 17, 2024

Donepezil in combination with memantine is a widely used clinical therapy for moderate to severe dementia. However, real-world population data on the long-term safety of donepezil are incomplete and variable. Therefore, aim this study was analyze adverse events (AEs) according US Food Drug Administration Adverse Event Reporting System (FAERS) provide evidence monitoring therapy.

Language: Английский

Citations

6
Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024 DOI Creative Commons
Xiaoling Zhong, Yihan Yang, Sheng Wei

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(3), P. e0309849 - e0309849

Published: March 24, 2025

Background Finasteride is commonly utilized in clinical practice for treating androgenetic alopecia, but real-world data regarding the long-term safety of its 0adverse events(AEs) remains incomplete, necessitating ongoing supplementation. This study aims to evaluate AEs associated with finasteride use, based on from US Food and Drug Administration Adverse Event Reporting System (FAERS), contribute assessment. Methods We reviewed AE reports database, covering period first quarter 2004 2024. assessed medication using four proportional disproportionality analyses: reported odds ratio (ROR), proportionate reporting (PRR), Bayesian Confidence Propagation Neural Network (BCPN), Multi-Item Gamma Poisson Shrinkage (MGPS). These methods were used whether there a significant association between drug use AEs. To investigate potential issues related we further analyzed similarities differences onset time by sex, as well age. Results A total 11,557 which was primary suspected analysed. The majority patients male (86.04%) proportion young adults aged 18-45 years (27.22%). 73 different categorised into 7 system organ classes (SOCs), common including erectile dysfunction sexual dysfunction. In addition, identified previously unlisted AEs, Peyronie’s disease post-5α reductase inhibitor syndrome. Of 102 occurred men women, depression anxiety being observed both sexes. When analysed age group, 17 ≤ 18 years, 157 18-65 133 ≥ 65 years. Common all groups included dysfunction, decreased libido, depression, suicidal ideation, psychotic disturbances attention disorders. median 61 days, occurring within month treatment. Notably, number persisted beyond one year Conclusion results our uncovered known novel medication. Some these identical specification, some them signaled that not demonstrated specification. showed variations sex study. Consequently, findings offer valuable insights future research are anticipated enhance safe practice.

Language: Английский

Citations

0
Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024 DOI Creative Commons
Xiaoling Zhong,

Yihan Yang,

Sheng Wei

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 22, 2024

Abstract Background Finasteride is commonly utilized in clinical practice for treating androgenetic alopecia, but real-world data regarding the long-term safety of its adverse events remains incomplete, necessitating ongoing supplementation. This study aims to evaluate (AEs) associated with finasteride use, based on from US Food and Drug Administration Adverse Event Reporting System (FAERS), contribute assessment. Methods We reviewed event reports FAERS database, covering period first quarter 2004 2024. assessed medication AEs using four proportional disproportionality analyses: reported odds ratio, proportionate reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPN), Multi-Item Gamma Poisson Shrinkage (MGPS). These methods were used AEs. whether there a significant association between drug use To investigate potential issues related we further analyzed similarities differences onset time by gender, as well age. Results Among 11,557 where was primary suspected drug, most patients affected male (86.04%), proportion being young adult aged 18-45 years (27.22%). categorized 73 into 7 different system organ categories (SOCs), which included common like erectile dysfunction sexual dysfunction. Notably, Peyronie’s disease post 5α reductase inhibitor syndrome not listed insert. identified 102 men women. Depression anxiety notable both female. Additionally, examined 17 under 18 old, 157 65 years, 133 older. Each age group exhibited unique AEs, although dysfunction, decreased libido, depression, suicidal ideation, psychotic disorder, attention disturbance observed across brackets. Ultimately, median all instances 61 days. The mainly within one month after initiation it noteworthy that second highest number cases involved reactions persisted beyond year treatment. Conclusion results our uncovered known novel medication. Some these identical specification, some them signaled demonstrated specification. In addition, showed variations gender study. Consequently, findings offer valuable insights future research are anticipated enhance safe practice.

Language: Английский

Citations

0